Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd Q3 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The presentation does not provide any revenue, sales, or volume figures for the quarter, nor any year-on-year changes. The investor presentation provides the following financial figures for the quarter: - EBITDA: ₹32.2 crore, up 16% year-on-year.
From Lincoln Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY25 investor presen
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key investor presentation takeaways from NGL Fine Chem Ltd's Q
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation — and how it ra
- Themis Medicare Ltd (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY25 investor presentation — and how i
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q3 FY25 results?
The presentation does not provide any revenue, sales, or volume figures for the quarter, nor any year-on-year changes. The investor presentation provides the following financial figures for the quarter: - EBITDA: ₹32.2 crore, up 16% year-on-year.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The presentation does not provide specific details on capex, capacity expansions, or new plants/projects, including amounts, status, or timelines.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.